NCT06084923View on ClinicalTrials.gov

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Chronic Lymphocytic Leukemia

Interventions

OTHER

Observation

Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected

All Listed Sponsors

lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER

NCT06084923 - Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | Biotech Hunter | Biotech Hunter